Back to Search
Start Over
PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease.
- Source :
- Clinical & Experimental Gastroenterology; Dec2023, Vol. 16, p237-247, 11p
- Publication Year :
- 2023
-
Abstract
- Background: Prostate-specific membrane antigen (PSMA) is highly and specifically upregulated in active-inflamed mucosa of patients with inflammatory bowel disease (IBD). We hypothesized that this upregulation would be detectable using a PSMA-targeted positron emission tomography/computed tomography (PET/CT) imaging agent, [<superscript>18</superscript>F]DCFPyL, enabling non-invasive visualization of inflammation. A noninvasive means of detecting active inflammation would have high clinical value in localization and management of IBD.Study: We performed [<superscript>18</superscript>F]DCFPyL imaging in three IBD patients with active disease. Abnormally increased gastrointestinal [<superscript>18</superscript>F]DCFPyL uptake was observed in areas with endoscopic, histologic, and immunohistochemical inflammation, demonstrating partial overlap of segments of bowel with abnormal [<superscript>18</superscript>F]DCFPyL uptake and active inflammation.Conclusion: This study demonstrates that PSMA-targeted [<superscript>18</superscript>F]DCFPyL PET can effectively detect regions of inflamed mucosa in patients with IBD, suggesting its utility as a non-invasive imaging agent to assess location, extent, and disease activity in IBD. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11787023
- Volume :
- 16
- Database :
- Complementary Index
- Journal :
- Clinical & Experimental Gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 174633905
- Full Text :
- https://doi.org/10.2147/CEG.S404009